title: Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?
authors.affiliation: Section of Cardiology, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Tariq
authors.initials: T
authors.lastname: Ahmad
authors.affiliation: Division of Cardiology, Stony Brook University, Stony Brook, NY, USA.
authors.forename: Javed
authors.initials: J
authors.lastname: Butler
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D012107:Research Design; D000069552:Rivaroxaban / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban